Nano-Derived Therapeutic Formulations with Curcumin in Inflammation-Related Diseases

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Due to its vast therapeutic potential, the plant-derived polyphenol curcumin is utilized in an ever-growing number of health-related applications. Here, we report the extraction methodologies, therapeutic properties, advantages and disadvantages linked to curcumin employment, and the new strategies addressed to improve its effectiveness by employing advanced nanocarriers. The emerging nanotechnology applications used to enhance CUR bioavailability and its targeted delivery in specific pathological conditions are collected and discussed. In particular, new aspects concerning the main strategic nanocarriers employed for treating inflammation and oxidative stress-related diseases are reported and discussed, with specific emphasis on those topically employed in conditions such as wounds, arthritis, or psoriasis and others used in pathologies such as bowel (colitis), neurodegenerative (Alzheimer's or dementia), cardiovascular (atherosclerosis), and lung (asthma and chronic obstructive pulmonary disease) diseases. A brief overview of the relevant clinical trials is also included. We believe the review can provide the readers with an overview of the nanostrategies currently employed to improve CUR therapeutic applications in the highlighted pathological conditions.

Related collections

Most cited references 176

Record: found
Abstract: found
Article: not found

Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019

David J Newman, Gordon M. Cragg (2020)

This review is an updated and expanded version of the five prior reviews that were published in this journal in 1997, 2003, 2007, 2012, and 2016. For all approved therapeutic agents, the time frame has been extended to cover the almost 39 years from the first of January 1981 to the 30th of September 2019 for all diseases worldwide and from ∼1946 (earliest so far identified) to the 30th of September 2019 for all approved antitumor drugs worldwide. As in earlier reviews, only the first approval of any drug is counted, irrespective of how many "biosimilars" or added approvals were subsequently identified. As in the 2012 and 2016 reviews, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions, and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/or synthetic variations using their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from 1946 to 1980, of the 75 small molecules, 40, or 53.3%, are N or ND. In the 1981 to date time frame the equivalent figures for the N* compounds of the 185 small molecules are 62, or 33.5%, though to these can be added the 58 S* and S*/NMs, bringing the figure to 64.9%. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures, though as can be seen in the review there are still disease areas (shown in Table 2) for which there are no drugs derived from natural products. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are still able to identify only two de novo combinatorial compounds (one of which is a little speculative) approved as drugs in this 39-year time frame, though there is also one drug that was developed using the "fragment-binding methodology" and approved in 2012. We have also added a discussion of candidate drug entities currently in clinical trials as "warheads" and some very interesting preliminary reports on sources of novel antibiotics from Nature due to the absolute requirement for new agents to combat plasmid-borne resistance genes now in the general populace. We continue to draw the attention of readers to the recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated"; thus we consider that this area of natural product research should be expanded significantly.

0 comments Cited 1089 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

The COVID-19 Cytokine Storm; What We Know So Far

Dina Ragab, Haitham Salah Eldin, Mohamed Taeimah … (2020)

COVID-19 is a rapidly spreading global threat that has been declared as a pandemic by the WHO. COVID-19 is transmitted via droplets or direct contact and infects the respiratory tract resulting in pneumonia in most of the cases and acute respiratory distress syndrome (ARDS) in about 15 % of the cases. Mortality in COVID-19 patients has been linked to the presence of the so-called “cytokine storm” induced by the virus. Excessive production of proinflammatory cytokines leads to ARDS aggravation and widespread tissue damage resulting in multi-organ failure and death. Targeting cytokines during the management of COVID-19 patients could improve survival rates and reduce mortality.

0 comments Cited 780 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Natural products in drug discovery: advances and opportunities

Atanas Atanasov, Sergey B. Zotchev, Verena Dirsch … (2021)

Natural products and their structural analogues have historically made a major contribution to pharmacotherapy, especially for cancer and infectious diseases. Nevertheless, natural products also present challenges for drug discovery, such as technical barriers to screening, isolation, characterization and optimization, which contributed to a decline in their pursuit by the pharmaceutical industry from the 1990s onwards. In recent years, several technological and scientific developments — including improved analytical tools, genome mining and engineering strategies, and microbial culturing advances — are addressing such challenges and opening up new opportunities. Consequently, interest in natural products as drug leads is being revitalized, particularly for tackling antimicrobial resistance. Here, we summarize recent technological developments that are enabling natural product-based drug discovery, highlight selected applications and discuss key opportunities.

0 comments Cited 743 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Natália Cruz-Martins:

ORCID: https://orcid.org/0000-0002-5934-5201

Javad Sharifi-Rad:

ORCID: https://orcid.org/0000-0002-7301-8151

Gianfranco Pintus:

ORCID: https://orcid.org/0000-0002-3031-7733

William C. Cho:

ORCID: https://orcid.org/0000-0003-4174-4586

Journal

Journal ID (nlm-ta): Oxid Med Cell Longev

Journal ID (iso-abbrev): Oxid Med Cell Longev

Journal ID (publisher-id): OMCL

Title: Oxidative Medicine and Cellular Longevity

Publisher: Hindawi

ISSN (Print): 1942-0900

ISSN (Electronic): 1942-0994

Publication date Collection: 2021

Publication date (Electronic): 15 September 2021

Volume: 2021

Electronic Location Identifier: 3149223

Affiliations

¹Facultad de Ciencias de la Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, Iquique 1110939, Chile

²Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, Porto, Portugal

³Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal

⁴Institute of Research and Advanced Training in Health Sciences and Technologies (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, PRD, Portugal

⁵Department of Scienze della Vita e dell'Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy

⁶Department of Plant Physiology, Faculty of Agrobiology and Food Resources, Slovak University of Agriculture, 94976 Nitra, Slovakia

⁷Department of Plant Biology, Educational and Scientific Center “Institute of Biology and Medicine”, Kiev National University of Taras Shevchenko, Volodymyrska, 64, 01033 Kyiv, Ukraine

⁸Department of Drug Technology and Biopharmaceutics, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, Ukraine

⁹Department of Pharmacognosy and Medical Botany, I. Horbachevsky Ternopil National Medical University, Voli 1, Ternopil, Ukraine

¹⁰Chemical and Biochemical Processing Division, ICAR–Central Institute for Research on Cotton Technology, Mumbai 400019, India

¹¹Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

¹²Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, 4070386 Concepcion, Chile

¹³Unidad de Desarrollo Tecnológico, Universidad de Concepción UDT, Concepcion 4070386, Chile

¹⁴Department of Medical Laboratory Sciences, College of Health Sciences and Sharjah Institute for Medical Research, University of Sharjah, 22272 Sharjah, UAE

¹⁵Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy

¹⁶Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong

Author notes

Academic Editor: Felipe L. de Oliveira

Author information

Natália Cruz-Martins https://orcid.org/0000-0002-5934-5201

Nataliia Hudz https://orcid.org/0000-0002-2240-0852

Manoj Kumar https://orcid.org/0000-0002-4192-6497

Yasaman Taheri https://orcid.org/0000-0002-0836-236X

Miquel Martorell https://orcid.org/0000-0003-3183-7623

Javad Sharifi-Rad https://orcid.org/0000-0002-7301-8151

Gianfranco Pintus https://orcid.org/0000-0002-3031-7733

William C. Cho https://orcid.org/0000-0003-4174-4586

Article

DOI: 10.1155/2021/3149223

PMC ID: 8470924

PubMed ID: 34584616

SO-VID: 4dfbe43f-e286-43de-bb87-bd46231d19ab

License:

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

History

Date received : 10 June 2021

Date accepted : 29 August 2021

Funding

Funded by: University of Sassari

Funded by: University of Sharjah

Award ID: 2101050160

Award ID: 2001050151

Funded by: Comisión Nacional de Investigación Científica y Tecnológica

Award ID: AFB170007

Funded by: Fundação para a Ciência e a Tecnologia

Award ID: PTDC/PSI-GER/28076/2017

Comments

Comment on this article

scite_

Cited by 18

See all cited by

Most referenced authors 2,353

See all reference authors

- Version 1

Nano-Derived Therapeutic Formulations with Curcumin in Inflammation-Related Diseases

Read this article at

Abstract

Related collections

Research from Ukraine

Most cited references 176

Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019

The COVID-19 Cytokine Storm; What We Know So Far

Natural products in drug discovery: advances and opportunities

Author and article information

Contributors

Journal

Affiliations

Author notes

Author information

Article

History

Funding

Categories

Comments

Comment on this article

Similar content 481

Cited by 18

Most referenced authors 2,353